Safracins, new antitumor antibiotics. III. Biological activity.
Safracins, new antitumor antibiotics. III. Biological activity.
复制标题
Safracins，新型抗肿瘤抗生素。
DOI：
--
复制
发表时间：
1983
期刊：
影响因子：
--
通讯作者：
T. Munakata
中科院分区：
文献类型：
--
作者：
Y. Ikeda;Y. Shimada;K. Honjo;T. Okumoto;T. Munakata
金黄色葡萄球菌A和B对革兰氏阳性菌和革兰氏阴性菌均有体外抗菌活性，但对感染金黄色葡萄球菌的小鼠无治疗作用。藏红花素A和B可引起大肠杆菌细胞的形态异常改变。对可移植的小鼠肿瘤的测试表明，Safracins A和B抑制P388白血病和IMC肿瘤的生长。
Safracins A and B have antibacterial activity against Gram-positive and Gram-negative bacteria in vitro but no therapeutic activity in mice infected with Staphylococcus aureus. Safracins A and B induce abnormal morphological changes in Echerichia coli cells. Tests with transplantable mice tumors demonstrate that safracins A and B inhibit the growth of P388 leukemia and IMC carcinoma.